title: Serum p24 antigen level as an intermediate end point in clinical trials of zidovudine in people infected with human immunodeficiency virus type 1. Aids Clinical Trials Group Virology Laboratories.
abstract: Serum p24 antigen levels were examined in subjects from three clinical trials of zidovudine to determine whether the pattern of change in serum p24 antigen during the first 8-16 weeks of therapy was associated with human immunodeficiency virus type 1 (HIV-1) disease progression or death. Among 406 patients with AIDS and a first episode of Pneumocystis carinii pneumonia, 65% had measurable pretreatment concentrations of serum p24 antigen (> or = 10 pg/mL). Changes during treatment were not associated with reduced mortality. In 637 mildly symptomatic patients, 24% had measurable concentrations, and changes were marginally associated with increased time until more advanced disease. Among 683 asymptomatic patients, 18% had measurable concentrations, and changes were not associated with increased time until progression. Despite the small number of clinical events and the low rate of serum p24 antigen positivity in the latter two studies, pretreatment serum p24 antigen levels were predictive of clinical outcome; subsequent measurements appear to be of limited use in evaluating zidovudine therapy.
authors.affiliation: Department of Biostatistics, Harvard School of Public Health, Boston, Massachusetts.
authors.forename: V
authors.initials: V
authors.lastname: DeGruttola
authors.forename: L A
authors.initials: LA
authors.lastname: Beckett
authors.forename: R W
authors.initials: RW
authors.lastname: Coombs
authors.forename: J M
authors.initials: JM
authors.lastname: Arduino
authors.forename: H H
authors.initials: HH
authors.lastname: Balfour
authors.forename: S
authors.initials: S
authors.lastname: Rasheed
authors.forename: F B
authors.initials: FB
authors.lastname: Hollinger
authors.forename: M A
authors.initials: MA
authors.lastname: Fischl
authors.forename: P
authors.initials: P
authors.lastname: Volberding
mesh_terms: D000386:AIDS-Related Complex / Q000453:epidemiology; D000163:Acquired Immunodeficiency Syndrome / Q000453:epidemiology; D000328:Adult; D004311:Double-Blind Method; D005260:Female; D005500:Follow-Up Studies; D016655:HIV Core Protein p24 / Q000097:blood*; D015658:HIV Infections / Q000188:drug therapy* / Q000209:etiology / Q000401:mortality; D015497:HIV-1 / Q000276:immunology*; D006801:Humans; D008297:Male; D011020:Pneumonia, Pneumocystis / Q000453:epidemiology; D016016:Proportional Hazards Models; D012307:Risk Factors; D016019:Survival Analysis; D013997:Time Factors; D015215:Zidovudine / Q000627:therapeutic use*
chemical_list: D016655:HIV Core Protein p24; D015215:Zidovudine